PTGX
Protagonist Therapeutics, Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Protagonist Therapeutics has 0 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceWe discovered rusfertide, advanced it into Phase 3 development, and in early 2024 entered into a co-development and co-commercialization arrangement with Takeda Pharmaceuticals, Inc. ("Takeda") under a license and collaboration agreement entered into in January 2024.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputs8Q avg ±3.1%·×1.81·rich
straddle ±7.7%
spot 144.85exp Nov 20ATM strike 145ATM straddle 13.20IV 48%
+6.45%
vs ±11.8% implied · ×0.55
shaded = implied · ▲▼ = realized
Linked news
—
Protagonist Therapeutics, Inc
144.19
−0.15 · −0.11%
post 144.17 −0.01%